ClinicalTrials.gg
CompletedNCT04484142Updated Mar 24, 2026Results posted

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

A Phase 2 interventional study of DS-1062a in Non-small Cell Lung Cancer, sponsored by Daiichi Sankyo. Completed at 84 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by Daiichi Sankyo · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
137
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung — 7 open to participants now, 19 under way, 9 of them phase 3. datopotamab deruxtecan · Carcinoma, Non-Small-Cell Lung.

Enrollment
16th of 21
137 · median 278
Started
2021
with 2 others
Phase 2
7 of 21
3 open now
Registered
3rd of 21
by date
Lead sponsor
6 of 21
Daiichi Sankyo

Among the 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung, this one is the 16th largest by enrollment, is one of 3 that started in 2021, is one of 7 in phase 2, and was the 3rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

7 of the 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About datopotamab deruxtecan

datopotamab deruxtecan: first FDA approval 2025 (DATROWAY), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung cancer (NSCLC) with known actionable genomic alterations.

Read the detailed description

This study will evaluate DS-1062a 6.0 mg/kg in participants with advanced or metastatic NSCLC with actionable genomic alterations and who have been previously been treated with 1 platinum-containing therapy and 1 or more lines of targeted therapy. The study will be divided into 3 periods: Screening Period, Treatment Period, and Follow-up Period. The primary analysis of Objective Response Rate (ORR) by blinded Independent Central Review (BICR) will be conducted after all participants either have been followed for at least 9 months after the start of study treatment or have discontinued from the study, whichever occurs first.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • Metastatic Non-small Cell Lung Cancer
  • Advanced Metastatic Non-small Cell Lung Cancer
  • Non-small Cell Lung Cancer
  • DS-1062a
  • Datopotamab Deruxtecan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants eligible for inclusion in the study must meet all inclusion criteria for this study.

  • Sign and date the inform consent form (ICF) prior to the start of any study- specific qualification procedures.
  • Adults ≥18 years (if the legal age of consent is >18 years old, then follow local regulatory requirements)
  • Has documented NSCLC that:

    1. Has stage IIIB, IIIC, or stage IV NSCLC disease at the time of enrollment (based on the American Joint Committee on Cancer, Eighth Edition).
    2. Has one or more of the following documented activating genomic alterations: EGFR, ALK, ROS1, NTRK, BRAF, MET exon 14 skipping, or RET.

KRAS mutations in the absence of any of the genomic alterations specified above will be excluded.

Overexpression of EGFR, in the absence of activating mutations, is NOT sufficient for enrollment.

Participants who have not received osimertinib should be evaluated for the presence of EGFR T790M mutation after relapse/progression on/after the most recent EGFR tyrosine kinase inhibitor (TKI), unless the participant is already known to be positive with document results for this mutation or unless osimertinib is not locally approved.

  • Has documentation of radiographic disease progression while on or after receiving the most recent treatment regimen for advanced or NSCLC.
  • Participant must meet the following for advanced or metastatic NSCLC:

    1. Has been treated with at least one but no more than two cytotoxic agent-containing therapy in the metastatic setting:

      • One platinum-containing regimen (either as monotherapy or combination therapy).
      • May have received up to one additional line of cytotoxic agent-containing therapy.
      • Those who received a platinum-containing regimen as therapy for early stage disease must have or progressed while on the treatment or within 6 months of the last dose OR received at least one additional course of platinum-containing therapy (which may or may not be same as in the adjuvant setting) for relapsed/progressive disease.
    2. May have received up to one (CPI)-containing regimen (may be in combination with a cytotoxic agent as part of a regimen described above or as an additional CPI regimen without a cytotoxic agent).
    3. Has been treated with 1 or more lines of non-CPI targeted therapy that is locally approved for the participant's applicable genomic alteration at the time of screening:

      • Those who received a targeted agent for the applicable genomic alterations in the study as adjuvant therapy for early stage disease must have relapsed or progressed while on the treatment or within 6 months of the last dose OR received at least one additional course of targeted therapy for the same genomic alterations (which may or may not be same agent used in the adjuvant setting) for relapsed/progressive disease.
      • Participants who have been treated with a prior TKI must receive additional targeted therapy, if clinically appropriate, for the genomic alterations that are considered amenable or the participant will not be allowed in the study.
  • Must undergo a mandatory pre-treatment tumor procedure or if available, a tumor biopsy that was recently collected (within 3 months of screening) after completion of the most recent anticancer treatment regimen and that has a minimum of 10 × 4 micron sections or a tissue block equivalent of 10 × 4 micron sections may be substituted for the mandatory biopsy collected during screening.
  • based on local imaging assessment using v1.1.
  • performance status (ECOG PS) of 0 - 1 at screening.

Exclusion criteria

Exclusion Criteria:

Participants meeting any exclusion criteria for this study will be excluded from this study.

  • Has spinal cord compression or clinically active central nervous system , defined as untreated and symptomatic, or requiring therapy with or anticonvulsants to control associated symptoms. Participants with clinically inactive may be included in the study.
  • Has .
  • Has prior treatment with:

    1. Any chemotherapeutic agent targeting topoisomerase I, including antibody drug conjugate (ADC) containing such agent.
    2. TROP2-targeted therapy.
  • Uncontrolled or significant cardiovascular disease:

    1. History of myocardial infarction within 6 months prior to Cycle 1 Day 1.
    2. History of uncontrolled angina pectoris within 6 months prior to Cycle 1 Day 1.
    3. Symptomatic congestive heart failure (CHF) ( Class II to IV) at screening. Participants with a history of Class II to IV CHF prior to screening must have returned to Class I CHF and have ≥50% (by either an ECHO or MUGA scan within 28 days of Cycle 1 Day 1) in order to be eligible.
    4. History of serious cardiac arrhythmia requiring treatment.
    5. LVEF \<50% or institutional lower limit of normal by ECHO or MUGA scan.
    6. Uncontrolled hypertension (resting systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg).
  • Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  • Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
  • corneal disease.
  • Has other primary , except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other solid tumors curatively treated, with no evidence of disease for ≥3 years.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
137 participants (actual)

Study arms

  • Experimental
    DS-1062a 6.0 mg/kg

    Participants will receive 6.0 mg/kg of DS-1062a

    Drug: DS-1062a

Interventions

  • DS-1062a will be administered as an intravenous (IV) infusion once every 3 weeks

    Also known as: Datopotamab Deruxtecan

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR)

    ORR is defined as the proportion of participants with a best overall response of confirmed complete response (CR) or confirmed partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.

Secondary outcomes

  1. Duration of Response (DOR)

    Time frame: From baseline up to approximately 24 months

  2. Progression-free Survival (PFS)

    Time frame: From baseline up to approximately 24 months

  3. Overall Survival (OS)

    Time frame: From baseline up to approximately 24 months

  4. Pharmacokinetic Parameter Maximum Concentration (Cmax)

    Time frame: From baseline up to approximately 24 months

  5. Pharmacokinetic Parameter Time to Maximum Concentration (Tmax)

    Time frame: From baseline up to approximately 24 months

  6. Pharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC)

    Time frame: From baseline up to approximately 24 months

  7. Percentage of Participants Who Reported Treatment-emergent Adverse Events (TEAE)

    Time frame: From baseline up to approximately 24 months

07

Results

Posted Apr 3, 2024

Participant flow

A total of 137 participants who met all inclusion criteria and no exclusion criteria were enrolled to receive Dato-DXd treatment in 50 clinical sites, North America= 15, Europe= 14, Asia Pacific= 21.

Participant flow — Overall Study
MilestoneDato DXd 6.0 mg/kg Q3W
Started137
Completed20
Not completed117
Withdrew: Adverse event13
Withdrew: Progressive disease87
Withdrew: Clinical progression10
Withdrew: Withdrawal by subject6
Withdrew: Physician decision1

Outcome measures

PrimaryPercentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR)

ORR is defined as the proportion of participants with a best overall response of confirmed complete response (CR) or confirmed partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

Time frame:
From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR)
percentage of participantsDato DXd 6.0 mg/kg Q3W
Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR)35.8 (27.8 to 44.4)
SecondaryDuration of Response (DOR)
Time frame:
From baseline up to approximately 24 months

Results for this outcome have not been posted.

SecondaryProgression-free Survival (PFS)
Time frame:
From baseline up to approximately 24 months

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)
Time frame:
From baseline up to approximately 24 months

Results for this outcome have not been posted.

SecondaryPharmacokinetic Parameter Maximum Concentration (Cmax)
Time frame:
From baseline up to approximately 24 months

Results for this outcome have not been posted.

SecondaryPharmacokinetic Parameter Time to Maximum Concentration (Tmax)
Time frame:
From baseline up to approximately 24 months

Results for this outcome have not been posted.

SecondaryPharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC)
Time frame:
From baseline up to approximately 24 months

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Reported Treatment-emergent Adverse Events (TEAE)
Time frame:
From baseline up to approximately 24 months

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events (AE) were collected from the date of first treatment, up to 24 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dato DXd 6.0 mg/kg Q3W68/137 (49.6%)34/137 (24.8%)135/137 (98.5%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventDato DXd 6.0 mg/kg Q3W
DyspnoeaRespiratory, thoracic and mediastinal disorders4/137
PneumonitisRespiratory, thoracic and mediastinal disorders3/137
COVID-19Infections and infestations2/137
CataractEye disorders1/137
GlaucomaEye disorders1/137
Abdominal pain upperGastrointestinal disorders1/137
DysphagiaGastrointestinal disorders1/137
Gastric perforationGastrointestinal disorders1/137
StomatitisGastrointestinal disorders1/137
VomitingGastrointestinal disorders1/137
Most frequent other events
Showing 10 of 40
Most frequent other events
EventDato DXd 6.0 mg/kg Q3W
NauseaGastrointestinal disorders82/137
StomatitisGastrointestinal disorders79/137
AlopeciaSkin and subcutaneous tissue disorders70/137
ConstipationGastrointestinal disorders43/137
Decreased appetiteMetabolism and nutrition disorders37/137
FatigueGeneral disorders34/137
VomitingGastrointestinal disorders31/137
AnaemiaBlood and lymphatic system disorders21/137
AstheniaGeneral disorders21/137
RashSkin and subcutaneous tissue disorders21/137

Baseline characteristics

The baseline demographic characteristics were assessed in the Full Analysis Set, which includes all subjects who received at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)Dato DXd 6.0 mg/kg Q3W
<=18 years0
Between 18 and 65 years91
>=65 years46
Age, Continuous
Age, Continuous(years)Dato DXd 6.0 mg/kg Q3W
Mean59.5 ± 11.15
Sex: Female, Male
Sex: Female, Male(Participants)Dato DXd 6.0 mg/kg Q3W
Female83
Male54
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dato DXd 6.0 mg/kg Q3W
American Indian or Alaska Native0
Asian78
Native Hawaiian or Other Pacific Islander0
Black or African American0
White43
More than one race15
Unknown or Not Reported1
08

Study locations

84 sites
  • Mayo Clinic
    Phoenix, Arizona 85259, United States
  • University of California San Diego
    La Jolla, California 92093, United States
  • UCLA
    Santa Monica, California 90404, United States
  • Boca Raton Regional Hospital
    Boca Raton, Florida 33486, United States
  • Sarah Cannon Research Institute at Florida Cancer Center, North
    Gainesville, Florida 32605, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • AdventHealth Orlando
    Orlando, Florida 32804, United States
  • Sarah Cannon Research Institute at Florida Cancer Center, South
    Port Charlotte, Florida 33980, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • The Office of Dr. Frederick P. Smith MD
    Chevy Chase, Maryland 20815, United States
  • Massachusetts General Hospital Cancer Center
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Michigan
    Detroit, Michigan 48202, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • XCancer / Regional Cancer Care Associate (Astera)
    East Brunswick, New Jersey 08816, United States
  • NYU Langone Medical Center
    New York, New York 10016, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • New York Cancer and Blood Specialists
    Port Jefferson, New York 11776, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • Avera Cancer Institute Sioux Falls
    Sioux Falls, South Dakota 57105, United States
  • Sarah Cannon Research Institute at Tennessee Oncology - Chattanooga
    Chattanooga, Tennessee 37404, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Mary Crowley Cancer Research
    Dallas, Texas 75230, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Virginia Cancer Specialists
    Athens, Virginia 30607, United States
  • Kadlec Clinic Hematology and Oncology
    Kennewick, Washington 99336, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 33612, United States
  • APHM - Hopital Nord
    Marseille, Bouches-Du-Rhône 13015, France
  • University Hospital of Nantes
    Nantes, Loire-Atlantique 44000, France
  • CHU Toulouse Hopital Larrey
    Toulouse, Occitanie 31059, France
  • Centre Leon Berard
    Lyon, Rhone 69008, France
  • CHU Louis Pradel
    Lyon, 69003, France
  • Institut Curie
    Paris, 75005, France
  • Hopitaux Universitaire de Strasbourg- Nouvel Hopital Civil
    Strasbourg, 67091, France
  • Centre Hospitalier Intercommunal Toulon La Seyne sur mer Hopital Sainte-Musse
    Toulon, 83000, France
  • Gustav Roussy Cancer Campus Grand Paris
    Villejuif, Île-de-France Region 94805, France
  • Thoraxklinik Heidelberg
    Heidelberg, Baden-Wurttemberg 69126, Germany
  • Asklepios Fachklinik Muenchen-Gauting
    Gauting, Bavaria 82131, Germany
  • IKF Krankenhaus Nordwest
    Frankfurt am Main, Hesse 60488, Germany
  • Universitaet zu Koeln - Uniklinik Koeln
    Cologne, North Rhine-Westphal 50937, Germany
  • Medizinische Hochschule Hannover
    Hanover, 30625, Germany
  • Thoraxklinik Heidelberg gGmbH
    Heidelberg, 69126, Germany
  • National Koranyi Institute for TB and Pulmonology
    Budapest, H-1121, Hungary
  • Pulmonology Hospital Törökbálint
    Törökbálint, H-2045, Hungary
  • Azienda Ospedaliera Universitaria Policlinico-OVE
    Catania, CT 95030, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Rome, RM 00168, Italy
  • University of Turin San Luigi Hospital
    Orbassano, Torino 10043, Italy
  • Azienda Ospedaliero-Universitaria S. Orsola Malpighi
    Bologna, 40138, Italy
  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
    Milan, 20122, Italy
  • Istituto Europeo di Oncologia
    Milan, 20141, Italy
  • Azienda Ospedaliero Universitaria di Parma
    Parma, 43126, Italy
  • Azienda Ospedaliera Arcispedale Santa Maria
    Reggio Emilia, 42123, Italy
  • Fujita Health University Hospital
    Toyoake-shi, Aichi-ken 470-1192, Japan
  • National Cancer Center Hospital East
    Kashiwa-shi, Chiba 277-8577, Japan
  • Hokkaido Cancer Center
    Sapporo, Hokkaido 003-0804, Japan
  • Kyoto University Hospital
    Kyoto, Kyoto 606-8507, Japan
  • Niigata Cancer Center Hospital
    Niigata, Niigata 961-8566, Japan
  • Kansai Medical University Hospital
    Hirakata-shi, Osaka 573-1191, Japan
  • Osaka City General Hospital
    Osaka, Osaka 534-0021, Japan
  • Osaka International Cancer Institute
    Osaka, Osaka 541-8567, Japan
  • Kindai University Hospital
    Ōsaka-sayama, Osaka 589-8511, Japan
  • Shizuoka Cancer Center
    Nagaizumi-chō, Shizuoka 411-8777, Japan
  • Tokushima University Hospital
    Tokushima, Tokushima 770-8503, Japan
  • National Cancer Center Hospital
    Chuo Ku, Tokyo 104-0045, Japan
  • The Cancer Institute Hospital of JFCR
    Koto-Ku, Tokyo 135-8550, Japan
  • Aichi Cancer Center Hospital
    Aichi, 464-8681, Japan
  • The Netherlands Cancer Institute
    Amsterdam, North Holland 1066 CX, Netherlands
  • Erasmus MC
    Rotterdam, South Holland 3015 CD, Netherlands
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 110744, South Korea
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Severance Hospital
    Seoul, 03722, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
  • Samsung Medical Center
    Seoul, 6273, South Korea
  • Hospital Universitario Puerta de Hierro de Majadahonda
    Majadahonda, Madrid 28222, Spain
  • Hospital Regional Universitario Malaga
    Málaga, Malaga 29010, Spain
  • Hospital General Universitario de Alicante
    Alicante, 03010, Spain
  • Hospital Universitario Vall dHebron
    Barcelona, 08035, Spain
  • Hospital Clinic i Provincial de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • National Cheng Kung University Hospital
    Tainan, 70403, Taiwan
  • National Taiwan University Hospital NTUH
    Taipei, 100, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
  • Koo Foundation Sun Yat-Sen Cancer Center
    Taipei, 112, Taiwan
09

References and documents

Publications

  • Ahn MJ, Lisberg A, Goto Y, Sands J, Hong MH, Paz-Ares L, Pons-Tostivint E, Perol M, Felip E, Sugawara S, Hayashi H, Cho BC, Blumenschein G Jr, Shum E, Lee JS, Heist RS, Cornelissen R, Chang WC, Kowalski D, Zebger-Gong H, Chargualaf M, Gu W, Lan L, Howarth P, Joseph R, Okamoto I. A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC. J Thorac Oncol. 2025 Nov;20(11):1669-1682. doi: 10.1016/j.jtho.2025.06.002. Epub 2025 Jun 12. PubMed 40516821 ↗
  • Sands J, Ahn MJ, Lisberg A, Cho BC, Blumenschein G Jr, Shum E, Pons Tostivint E, Goto Y, Yoh K, Heist R, Shimizu J, Lee JS, Baas P, Planchard D, Perol M, Felip E, Su WC, Zebger-Gong H, Lan L, Liu C, Howarth P, Chiaverelli R, Paz-Ares L. Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study. J Clin Oncol. 2025 Apr;43(10):1254-1265. doi: 10.1200/JCO-24-01349. Epub 2025 Jan 6. PubMed 39761483 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Mar 2023, 23 months.

Results were first posted in Apr 2024, 1 year after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 23 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2020
First posted
Jul 23, 2020
StartActual
Mar 30, 2021
Primary completionActual
Mar 10, 2023
CompletionActual
Feb 4, 2026
Results first posted
Apr 3, 2024
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04484142
Lead sponsor
Daiichi Sankyo
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Jul 23, 2020
Start date
Mar 30, 2021
Primary completion
Mar 10, 2023
Completion
Feb 4, 2026
Results posted
Apr 3, 2024
Last update
Mar 24, 2026

Study contacts

Global Clinical Leader
study director · Daiichi Sankyo

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Datopotamab deruxtecan

Start the discussion